Pharmaceuticals & Biologics
Bringing pharmaceuticals and biologics to market means managing interconnected risk across clinical trials, regulatory requirements, manufacturing and global supply chains. Product liability, temperature-sensitive products and complex third-party relationships can create exposures that extend across markets and operations.
HUB’s Life Sciences specialists bring deep sector knowledge and a whole-enterprise view to help align insurance and risk management strategies with your products, operations and markets.
Stay Ahead of Industry Challenges
Complex products create risk across trials, manufacturing and global markets
Pharmaceutical and biologic organizations must manage risk across clinical development, manufacturing, supply chains and commercialization. Product characteristics, trial locations, regulatory requirements and third-party relationships can all affect the exposures an organization carries.
Product liability is one of the most significant exposures for pharmaceutical and biologic organizations. Adverse events, contamination, labelling issues, manufacturing defects and other product-related events can create significant liability, with exposure influenced by the product, patient population, manufacturing model and markets served.
HUB structures product liability protection around the organization’s products, operations and commercial footprint, considering manufacturing arrangements, supply chain dependencies, distribution and international exposures.
Product liability should reflect the realities of the product and how it reaches the market.
Protection aligned with the product portfolio, operating model and markets the organization serves.
Clinical trials can expose sponsors to liability arising from participant injury and other trial-related events. For multinational studies, insurance requirements can vary by country, including jurisdictions requiring locally admitted coverage or specific evidence of insurance before a trial can proceed.
HUB works with clinical trial sponsors to structure coverage around the study, trial locations and applicable insurance requirements, coordinating international programs where locally admitted coverage is required.
A global clinical trial program must account for the requirements of every jurisdiction in which participants are enrolled.
Clinical trial protection structured around the study footprint and applicable local requirements.
Pharmaceutical and biologic organizations can depend on contract manufacturers, active pharmaceutical ingredient suppliers, laboratories, distributors and temperature-controlled logistics. Contamination, sterility issues, temperature excursions or other supply chain failures can affect product quality and continuity.
HUB assesses supply chain dependencies, contractual risk transfer, manufacturing relationships and temperature-sensitive exposures alongside product liability, property and other relevant coverage.
Outsourced manufacturing and distribution can change where risk originates without eliminating the organization’s exposure.
A clearer view of risk across manufacturing, supply chain and distribution relationships.
Tailored Risk Solutions for Your Industry
Connect product, clinical and operational risk across the enterprise
Risk can vary significantly across pharmaceutical and biologic organizations. HUB begins with the products being developed or commercialized, where trials and operations take place, how products are manufactured and distributed and where responsibility sits across third-party relationships. From there, our specialists help build a coordinated strategy around the organization’s specific exposures.
Product liability is structured around the product portfolio, patient and use profile, manufacturing model and commercial footprint. Clinical trial liability can be coordinated across study locations, including international programs where local insurance requirements or admitted coverage apply.
HUB considers contract manufacturing, suppliers, temperature-controlled logistics and distribution alongside property, equipment and business interruption exposures. Depending on the organization, protection can also address recall expense and intellectual property risks.
HUB’s capabilities include supply chain risk assessment, contractual risk transfer, international program coordination, industry-specific benchmarking, M&A due diligence, management systems and safety, environmental and regulatory compliance.
Industry Insights
Insights and resources for pharmaceutical and biologic organizations
